Literature DB >> 2573423

Mechanisms of inhibition of DNA synthesis by 2-chlorodeoxyadenosine in human lymphoblastic cells.

J Griffig1, R Koob, R L Blakley.   

Abstract

2-Chloro-2'-deoxyadenosine 5'-triphosphate (CldATP) is a strong inhibitor of the reduction of ADP, CDP, UDP and GDP by ribonucleotide reductase in extracts of CCRF-CEM with 50% inhibition at concentrations of 0.1 to 0.3 microM. In cells exposed to 0.3 microM 2-chloro-2'-deoxyadenosine (CldAdo), the intracellular concentration of CldATP reaches 2 microM within 15 min, and DNA synthesis by the cells is inhibited 90% within 30 min. At concentrations of extracellular CldAdo that inhibit DNA synthesis, there is also marked inhibition of intracellular conversion of cytidine to deoxycytidine nucleotides indicating significant intracellular inhibition of ribonucleotide reductase. Exposure of cells to 0.3 microM CldAdo decreases dCTP by 63% in 30 min, dATP and dTTP by 20% and dGTP by a smaller amount. Similar decreases in these pools occur when other inhibitors of ribonucleotide reductase are present at concentrations causing similar inhibition of DNA synthesis. Deoxycytidine treatment of cells inhibited by CldAdo restores dCTP and other pools, but restoration of DNA synthesis is incomplete, indicating that there is another mechanism for inhibition of DNA synthesis in addition to depletion of deoxyribonucleotide pools. This alternate mechanism is probably related to the incorporation of CldAdo into DNA that occurs despite a 25-times lower intracellular level of CldATP than dATP.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2573423

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  27 in total

1.  Identification of Non-nucleoside Human Ribonucleotide Reductase Modulators.

Authors:  Md Faiz Ahmad; Sarah E Huff; John Pink; Intekhab Alam; Andrew Zhang; Kay Perry; Michael E Harris; Tessianna Misko; Suheel K Porwal; Nancy L Oleinick; Masaru Miyagi; Rajesh Viswanathan; Chris Godfrey Dealwis
Journal:  J Med Chem       Date:  2015-12-09       Impact factor: 7.446

2.  Effects of 2-chloroadenine substitution in DNA on restriction endonuclease cleavage reactions.

Authors:  P Hentosh; J C McCastlain
Journal:  Nucleic Acids Res       Date:  1991-06-11       Impact factor: 16.971

3.  Additional treatment with 2-Chloro-2-Deoxyadenosine during consolidation in children with high-risk acute myeloid leukemia does not improve survival.

Authors:  U Creutzig; M N Dworzak; M Zimmermann; J-P Bourquin; B Gruhn; G Fleischhack; N Graf; T Klingebiel; B Kremens; T Lehrnbecher; C von Neuhoff; A V Stackelberg; J Starý; D Reinhardt
Journal:  Leukemia       Date:  2015-04-14       Impact factor: 11.528

4.  Evaluating the therapeutic potential of a non-natural nucleotide that inhibits human ribonucleotide reductase.

Authors:  Md Faiz Ahmad; Qun Wan; Shalini Jha; Edward Motea; Anthony Berdis; Chris Dealwis
Journal:  Mol Cancer Ther       Date:  2012-08-28       Impact factor: 6.261

5.  Quantitation of synergism of arabinosylcytosine and cladribine against the growth of arabinosylcytosine-resistant human lymphoid cells.

Authors:  Tieran Han; Marilyn Fernandez; Ting-Chao Chou; Ram P Agarwal
Journal:  J Cancer Res Clin Oncol       Date:  2005-10-20       Impact factor: 4.553

Review 6.  Cladribine to Treat Relapsing Forms of Multiple Sclerosis.

Authors:  Gavin Giovannoni
Journal:  Neurotherapeutics       Date:  2017-10       Impact factor: 7.620

Review 7.  [Oral cladribine for relapsing-remitting multiple sclerosis: another purine analogue or a genuine therapeutic innovation?].

Authors:  S Schmidt
Journal:  Nervenarzt       Date:  2010-10       Impact factor: 1.214

Review 8.  Identification of targets and new developments in the treatment of multiple sclerosis--focus on cladribine.

Authors:  Clemens Warnke; Heinz Wiendl; Hans-Peter Hartung; Olaf Stüve; Bernd C Kieseier
Journal:  Drug Des Devel Ther       Date:  2010-07-21       Impact factor: 4.162

Review 9.  Cladribine. A review of its pharmacodynamic and pharmacokinetic properties and therapeutic potential in haematological malignancies.

Authors:  H M Bryson; E M Sorkin
Journal:  Drugs       Date:  1993-11       Impact factor: 9.546

10.  Polyadenylation inhibition by the triphosphates of deoxyadenosine analogues.

Authors:  Lisa S Chen; William Plunkett; Varsha Gandhi
Journal:  Leuk Res       Date:  2008-04-22       Impact factor: 3.156

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.